Navigation Links
China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
Date:12/1/2009

HARBIN, China, Dec. 1 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has engaged Guangdong Mediacy Kind Medical Devices Industry Service Company ("MDK") to serve as its exclusive sales agent for the Company's AMI Diagnostic Kit and Human Urinary Albumin Elisa Kit in Southeast Asia.

MDK's management team was impressed by China Sky One Medical's state-of-the-art production facilities and its strict quality control system. MDK, which performed its own market research and financial forecasts, has the utmost confidence in the market prospects of the Company's two new diagnostic kits. The distribution agreement has an initial trial period of three months. A more formal contract will be developed to define the annual sales guidelines.

The AMI Diagnostic Kit is used to diagnose early acute myocardial infarction and the Human Urinary Albumin Elisa Kit is used to diagnose early acute kidney disease. For the first nine months ended September 30, 2009, sales of the AMI Diagnostic Kit reached $7.5 million, accounting for approximately 7.5% of the Company's total revenues. Sales of the Human Urinary Albumin Elisa Kit reached $1.6 million, accounting for approximately 1.6% of the Company's total revenues, during the same period.

"We look forward to a successful collaboration with MDK on the sale of our AMI Diagnostic Kit and our Human Urinary Albumin Elisa Kit, both of which have huge market potential," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Our international sales team has already built a good market foundation in some Southeast Asian countries. We believe that MDK's mature sales network for medical devices will make this a mutually beneficial agreement."

"As part of our growth strategy, we will continue to expand our sales network in Southeast Asia, which is one of the most attractive overseas markets for China Sky One Medical due to its geographical and cultural proximity to China," Mr. Liu added.

About Guangdong Mediacy Kind Medical Devices Industry Service Company ("MDK")

Headquartered in Zhuhai, China, MDK is a professional medical devices supply chain service provider. MDK is known as a pioneer in its industry and introduced an international medical supply chain management system into China. MDK has built a wide business network in China as well as in other Asian countries, and recorded foreign sales revenues over $100 million over past twelve months. For more information, visit http://www.mdkchina.com .

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the business collaboration with MDK and other market expansion efforts. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451-53994069
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
2. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
3. China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information
4. Niusule Expands Geographic Footprint in China
5. China Pharma Holdings, Inc. to Present at Brean Murray China Growth Conference
6. China Business Knowledge Launches “China Prospects Forum” -- Dec. 9, 2009, New York City
7. China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter Fiscal 2010 Financial Results
8. China Biologic Schedules Conference Call to Discuss Third Quarter 2009 Financial Results
9. China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2009 Results
11. China Medicine Announces Conference Call to Discuss Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):